undamentalytics Newsletter
Sign in

Arcutis Biotherapeutics, Inc. balance sheet

At the end of fiscal 2025, Arcutis Biotherapeutics, Inc. had total assets of $433m, total liabilities of $243m and shareholders' equity of $189m. It held $42.9m in cash against $109m of debt: net debt of $66.1m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents65965488714334
Receivables—082673146155
Inventory—0813152339
Total current assets293403437330336411468
Total assets298408449341349433489
Accounts payable7791214137
Total current liabilities2333384781130160
Short-term debt———0017
Long-term debt072198202107108102
Total debt075200202107109109
Total liabilities28110240253191243268
Shareholders' equity27129821089158189221
Net debt (negative = net cash)−65−21146113366675
Shares outstanding43m50m61m—118m123m126m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ARQT vs CRMDARQT vs KRYSARDX vs ARQTADMA vs ARQT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Arcutis Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Arcutis Biotherapeutics, Inc.